[go: up one dir, main page]

PE20200444A1 - Terapia de combinacion para cancer de prostata - Google Patents

Terapia de combinacion para cancer de prostata

Info

Publication number
PE20200444A1
PE20200444A1 PE2019002030A PE2019002030A PE20200444A1 PE 20200444 A1 PE20200444 A1 PE 20200444A1 PE 2019002030 A PE2019002030 A PE 2019002030A PE 2019002030 A PE2019002030 A PE 2019002030A PE 20200444 A1 PE20200444 A1 PE 20200444A1
Authority
PE
Peru
Prior art keywords
prostate cancer
combination therapy
amount
combination
refers
Prior art date
Application number
PE2019002030A
Other languages
English (en)
Inventor
Margaret K Yu
Linda Anne Snyder
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200444(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20200444A1 publication Critical patent/PE20200444A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Referido a una combinacion que comprende una cantidad de niraparib, una cantidad de acetato de abiraterona, y una cantidad de prednisona. Tambien se refiere a una composicion farmaceutica que comprende dicha combinacion en una forma de dosificacion oral, y su uso como terapia para tratar el cancer de prostata.
PE2019002030A 2017-04-13 2018-04-09 Terapia de combinacion para cancer de prostata PE20200444A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Publications (1)

Publication Number Publication Date
PE20200444A1 true PE20200444A1 (es) 2020-02-28

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002030A PE20200444A1 (es) 2017-04-13 2018-04-09 Terapia de combinacion para cancer de prostata

Country Status (33)

Country Link
US (4) US20180296574A1 (es)
EP (3) EP3609497B1 (es)
JP (3) JP7141408B2 (es)
KR (1) KR20190134718A (es)
CN (2) CN110753545A (es)
AU (2) AU2018251594A1 (es)
CA (1) CA3059562A1 (es)
CL (1) CL2019002871A1 (es)
CO (1) CO2019011591A2 (es)
CR (1) CR20190467A (es)
DK (1) DK3609497T3 (es)
DO (1) DOP2019000264A (es)
EA (1) EA201992430A1 (es)
ES (1) ES2931052T3 (es)
HR (1) HRP20221327T1 (es)
HU (1) HUE060460T2 (es)
IL (2) IL269879B2 (es)
JO (1) JOP20190244A1 (es)
LT (1) LT3609497T (es)
MA (1) MA48728B1 (es)
MD (1) MD3609497T2 (es)
MX (2) MX2019012296A (es)
MY (1) MY209010A (es)
NI (1) NI201900105A (es)
PE (1) PE20200444A1 (es)
PH (1) PH12019502317A1 (es)
PL (1) PL3609497T3 (es)
PT (1) PT3609497T (es)
RS (1) RS63832B1 (es)
SG (1) SG11201909552VA (es)
SM (1) SMT202200467T1 (es)
UA (1) UA129514C2 (es)
WO (1) WO2018191141A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3490560T3 (fi) 2016-07-29 2025-02-27 Janssen Pharmaceutica Nv Niraparibi käytettäväksi eturauhassyövän hoitomenetelmässä
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
BR112022022590A2 (pt) * 2020-05-08 2022-12-13 Janssen Pharmaceutica Nv Formulações farmacêuticas de acetato de abiraterona e niraparibe
US11806313B2 (en) 2021-12-15 2023-11-07 Hunan Huize Biopharma S&T Co., Ltd. Abiraterone acetate containing composition and application thereof
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
KR20240170958A (ko) * 2022-04-07 2024-12-05 아스트라제네카 아베 암 치료를 위한 병용 요법
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
CN121443291A (zh) * 2023-08-02 2026-01-30 詹森药业有限公司 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CN101528308A (zh) 2006-08-25 2009-09-09 库伽尔生物科技公司 治疗癌症的方法和组合物
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
ES2548131T3 (es) 2008-01-08 2015-10-14 Merck Sharp & Dohme Limited Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
SG11201909552VA (en) 2019-11-28
RS63832B1 (sr) 2023-01-31
MX2019012296A (es) 2019-11-28
UA129514C2 (uk) 2025-05-21
MY209010A (en) 2025-06-16
CO2019011591A2 (es) 2020-02-28
JP7407880B2 (ja) 2024-01-04
NI201900105A (es) 2020-03-11
SMT202200467T1 (it) 2023-01-13
EP3609497A1 (en) 2020-02-19
EP4176879A1 (en) 2023-05-10
IL269879B2 (en) 2025-10-01
KR20190134718A (ko) 2019-12-04
JP7141408B2 (ja) 2022-09-22
HRP20221327T1 (hr) 2023-03-17
EA201992430A1 (ru) 2020-02-28
PT3609497T (pt) 2023-01-23
AU2018251594A1 (en) 2019-10-24
MA48728B1 (fr) 2022-10-31
PL3609497T3 (pl) 2023-01-23
CR20190467A (es) 2020-03-09
US20240245710A1 (en) 2024-07-25
JOP20190244A1 (ar) 2019-10-13
HUE060460T2 (hu) 2023-03-28
ES2931052T3 (es) 2022-12-23
IL269879B1 (en) 2025-06-01
CN110753545A (zh) 2020-02-04
MX2023009569A (es) 2023-08-22
AU2024202346A1 (en) 2024-05-02
DK3609497T3 (da) 2022-10-31
CL2019002871A1 (es) 2019-12-27
IL320452A (en) 2025-06-01
MD3609497T2 (ro) 2023-03-31
CA3059562A1 (en) 2018-10-18
CN119235874A (zh) 2025-01-03
JP2020516646A (ja) 2020-06-11
BR112019021466A2 (pt) 2020-05-12
MA48728A (fr) 2020-04-08
EP3609497B1 (en) 2022-10-12
JP2024023344A (ja) 2024-02-21
US20240398837A1 (en) 2024-12-05
EP4176878A1 (en) 2023-05-10
WO2018191141A1 (en) 2018-10-18
DOP2019000264A (es) 2020-07-15
US20180296574A1 (en) 2018-10-18
PH12019502317A1 (en) 2020-07-06
LT3609497T (lt) 2022-12-12
IL269879A (es) 2019-11-28
JP2022141881A (ja) 2022-09-29
US20220175801A1 (en) 2022-06-09
AU2024202346B2 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
PE20200444A1 (es) Terapia de combinacion para cancer de prostata
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2016002312A1 (es) Modulador del receptor de andrógeno y usos de este.
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MX2017013321A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
UY36075A (es) Derivados de tubulisina
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
CL2009001011A1 (es) Uso del compuesto 21-metoxi-17a-acetoxi-11ß-(4-n,n­-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona (cdb-4124) para tratar el cancer de mama; y uso de la combinacion de cdb-4124 con un inhibidor de aromatasa.
MX2018004177A (es) Terapia de combinacion para el tratamiento de cancer.
BR112018073518A2 (pt) métodos para sensibilização de células de câncer a um tratamento anticâncer, para potencialização do efeito terapêutico de um tratamento anticâncer e para tratamento de câncer, composição, modulador de canais de ânion regulados por volume, kit de peças, e, uso de um modulador de canais de ânion regulados por volume
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
BR112015026257A2 (pt) terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
MX2020001727A (es) Terapia de combinacion.
NZ711564A (en) Methods of treating colorectal cancer
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
SI3168214T1 (sl) Substituiran 2-tiokso-imidazolidin-4-on in njegovi spiro analogi, aktivne proti rakave sestavine, farmacevtski sestavki, medicinski pripravki, postopek za zdravljenje raka prostate
BR112018002530A2 (pt) combinações e usos e tratamentos destas
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2020003830A (es) Métodos para tratar el cáncer de próstata mediante la administración de acetato de abiraterona más prednisona con terapia de privación de andrógenos.
MX2024012369A (es) Terapia combinada para el tratamiento del cancer